RxDoctor Payments Data

Pavel Polskiy, MD

Family Medicine · Carmichael, CANPI 1386735777

Payments from drug & device makers

$27,864in general payments, 2019–2025

Across 1,466 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Nestle Healthcare Nutrition Inc.$2K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$27,33298%
  • Education$5322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)266$5,076
Novo Nordisk131$2,205
AstraZeneca(2 entities)63$2,082
Nestle Healthcare Nutrition Inc.91$1,621
GSK83$1,365
Boehringer Ingelheim58$1,293
Bayer47$1,215
Johnson & Johnson(2 entities)62$1,198
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC55$889
Astellas Pharma US Inc24$841
Novartis42$825
Pfizer43$710
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)55$590
Aimmune Therapeutics, Inc.19$497
Ironwood Pharmaceuticals, Inc27$471
Merck24$463
Amgen20$401
Neurocrine Biosciences, Inc.13$385
Takeda Pharmaceuticals U.S.A., Inc.29$357
Biogen24$337
Esperion Therapeutics, Inc.18$336
Amarin Pharma, Inc.18$310
Ardelyx, Inc.14$295
Sunovion Pharmaceuticals Inc.27$269
E.r. Squibb & Sons, L.L.C.13$269
MDD US Operations, LLC11$242
Sumitomo Pharma America, Inc.13$225
Lilly USA, LLC13$211
Vanda Pharmaceuticals Inc.13$201
Biohaven Pharmaceutical Holding Company Ltd.14$197
Biohaven Pharmaceuticals, Inc.14$190
Alk-abello, Inc8$161
Eisai Inc.8$134
Acadia Pharmaceuticals Inc9$131
Bristol Myers Squibb8$129
Neurelis, Inc.6$120
Sanofi-aventis U.S. LLC7$115
Hologic Sales And Service, LLC5$108
Exact Sciences6$107
Impel Pharmaceuticals Inc.1$105
Supernus Pharmaceuticals, Inc.5$94
Madrigal Pharmaceuticals3$91
Redhill Biopharma Inc.5$86
Corcept Therapeutics4$82
Livanova USA, Inc.3$62
Vivus LLC3$54
Kyowa Kirin, Inc.3$52
UCB, Inc.2$51
Cranial Technologies, Inc3$44
Scilex Pharmaceuticals Inc.2$39
Avanir Pharmaceuticals, Inc.2$38
Mannkind Corporation3$35
Hikma Pharmaceuticals USA2$34
Sanofi Pasteur Inc.2$33
Idorsia Pharmaceuticals US Inc2$31
Lifescan, Inc.2$31
Agios Pharmaceuticals, Inc.1$30
Teva Pharmaceuticals USA, Inc.2$30
Urovant Sciences Inc1$30
Amneal Pharmaceuticals LLC1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,864 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$276,724
Medicare patients
886
Services billed
3,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide388$363,503
CreonLipase/Protease/Amylase161$339,539
JardianceEmpagliflozin348$338,434
EliquisApixaban311$322,251
TrulicityDulaglutide262$280,744
ZenpepLipase/Protease/Amylase85$219,490
LinzessLinaclotide218$172,794
RybelsusSemaglutide117$142,791
XareltoRivaroxaban151$138,839
FarxigaDapagliflozin Propanediol145$111,716
MyrbetriqMirabegron126$98,744
TezspireTezepelumab-Ekko22$94,025
TradjentaLinagliptin96$88,872
Tresiba Flextouch U-200Insulin Degludec115$87,811
JanuviaSitagliptin Phosphate56$54,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$5,076$512,333379 claims
Novo NordiskOzempic, Rybelsus$2,205$506,294505 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$1,293$455,101490 claims
PfizerEliquis, Nurtec Odt$710$340,320323 claims
Lilly USA, LLCTrulicity, Mounjaro$211$331,944312 claims
AstraZenecaFarxiga, Tezspire, Breztri Aerosphere, Brilinta$2,082$256,335243 claims
Aimmune Therapeutics, Inc.Zenpep$497$219,49085 claims
Johnson & JohnsonXarelto$1,198$138,839151 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,365$113,044196 claims
MerckJanuvia, Janumet$463$101,846105 claims
Astellas Pharma US IncMyrbetriq$841$98,744126 claims
NovartisEntresto$825$45,45851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Carmichael

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →